Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK
- Non-Small Cell Lung Cancer
The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.
The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.
This is a multi-center retrospective observational research study collecting data for participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) up to 6 years before start of data collection and who have completed/stopped docetaxel treatment at least 30 days prior to data collection. The primary goal of this study is to describe the percentage of participants with at least one neutropenic sepsis (NS) episode following initiation of treatment with single-agent docetaxel. Data will be collected until end of docetaxel treatment plus an additional 30 days to allow for presentation with toxicity.
A Retrospective Chart Review to Describe the Rate of Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK
- Diagnosed with locally advanced or metastatic (stage Ill or IV) non-small cell lung cancer (NSCLC)
- Relapsed disease following, or unable to tolerate, at least one line of prior chemotherapy
- Initiated on single-agent docetaxel up to a maximum of 6 years prior to date of collection
- Aged 18 years at date of first docetaxel dose
- Completed or stopped treatment with docetaxel at least 30 days prior to date of data collection
- Receiving docetaxel in an interventional clinical trial
- For whom no details of absolute neutrophil count are recorded
For the latest version of this information please go to www.forpatients.roche.com